Preparation, in Vitro Release and Antibacterial Activity Evaluation of Rifampicin and Moxifloxacin-Loaded Poly(d,l-Lactide-co-glycolide) Microspheres.

ZeWen Qiao,Zhi Yuan,Wenping Zhang,Daihao Wei,Ningmin Hu
DOI: https://doi.org/10.1080/21691401.2019.1581792
2019-01-01
Artificial Cells Nanomedicine and Biotechnology
Abstract:Osteomyelitis is difficult to treat because infective bone is poorly accessible for intravenously administering antibiotics and biofilm formation increases bacterial resistance. In this study, microspheres prepared using poly(lactide-co-glycolide) (PLGA) and embedded with moxifloxacin (MOX-PLGA microspheres) and rifampicin/moxifloxacin (RIF/MOX-PLGA microspheres) using the water-in-oil-in-water double emulsion solvent evaporation technique were used for local delivery. Shape of MOX-PLGA microspheres and RIF/MOX-PLGA microspheres were spherical, mean particle size of them were 20.52m and 16.62m, respectively. Encapsulation efficiency of the MOX-PLGA microspheres was 17.35% +/- 2.42%. However, the encapsulation efficiency for MOX and RIF in RIF/MOX-PLGA microspheres was 33.25% +/- 7.51% and 49.0% +/- 11.25%, respectively. Moxifloxacin and rifampicin were released slowly from microspheres. Both microspheres can efficiently release antibiotics in vitro. Antibacterial and bacterial biofilm-inhibition properties of the released solution were investigated from RIF/MOX-PLGA, MOX-PLGA, and blank PLGA microspheres at varying time points in vitro. RIF/MOX-PLGA microspheres demonstrated the strongest antibacterial activity and bacterial biofilm-inhibition property than the other two microspheres (p<.05). This study suggests that the novel RIF/MOX-PLGA microspheres can be used as a promising carrier for osteomyelitis treatment.
What problem does this paper attempt to address?